Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15893669 | 0.93 | KMT2A (0.50) | KMT2AEPHX2TDP1CASP3NPC1 | |
| SCHEMBL15896484 | 0.80 | KMT2A (0.47) | KMT2AEPHX2CASP3RAB9A | |
| SCHEMBL7408626 | 0.80 | KMT2A (0.49) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL14756776 | 0.79 | KMT2A (0.51) | KMT2AEPHX2CASP3 | |
| SCHEMBL4091188 | 0.78 | KMT2A (0.49) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL2663589 | 0.78 | KMT2A (0.49) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL8236471 | 0.77 | KMT2A (0.70) | KMT2AEPHX2 | |
| SCHEMBL4572008 | 0.76 | KMT2A (0.73) | KMT2AEPHX2TLR2 | |
| SCHEMBL7132449 | 0.75 | KMT2A (0.75) | KMT2AEPHX2TLR2 | |
| SCHEMBL15893670 | 0.75 | KMT2A (0.59) | KMT2AEPHX2CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141324-A1 | STABLE PEPTIDE-BASED FURIN INHIBITORS | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141324-A1 | STABLE PEPTIDE-BASED FURIN INHIBITORS | FURIN, PREP, VIP | KMT2A 3976/4885EPHX2 2865/4885TDP1 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.